{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:19:43Z","timestamp":1789600783544,"version":"build-2803163510"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T00:00:00Z","timestamp":1576800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"BBIL","award":["CTRI\/2014\/02\/004386"],"award-info":[{"award-number":["CTRI\/2014\/02\/004386"]}]},{"name":"BBIL","award":["CTRI\/2016\/05\/006909"],"award-info":[{"award-number":["CTRI\/2016\/05\/006909"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This study reports immunogenicity, safety, and interchangeability of a single-dose, inactivated, Vero-cell derived, JENVAC to the live-attenuated SA 14-14-2 vaccine in healthy children.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This phase 4, multicenter, open-label, randomized, control trial enrolled 360 children who were equally randomized to receive a single dose of either JENVAC or SA 14-14-2. Children were followed at various time points, until 2 years (day 720) postvaccination, upon which a subset from each group was divided and allocated to a receive a booster dose or the other vaccine.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At all time points, immunological measures were statistically higher in the JENVAC group. In the interchangeability study, children receiving 2 doses of JENVAC reported significantly higher response compared with 2 doses of SA 14-14-2. No difference in adverse events was observed. These corroborate with excellent seroprotection after the first dose of an earlier JENVAC study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A single-dose vaccination with JENVAC induces protective titers that persist up to 1 year. We report appreciable interchangeability between both vaccines, with JENVAC\/JENVAC combination exhibiting the highest immune response. JENVAC is now licensed as a single-dose Japanese encephalitis vaccine.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiz672","type":"journal-article","created":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T12:08:31Z","timestamp":1576670911000},"page":"1478-1487","source":"Crossref","is-referenced-by-count":21,"title":["Persistence of Immune Responses With an Inactivated Japanese Encephalitis Single-Dose Vaccine, JENVAC and Interchangeability With a Live-Attenuated Vaccine"],"prefix":"10.1093","volume":"222","author":[{"given":"Krishna Mohan","family":"Vadrevu","sequence":"first","affiliation":[{"name":"Bharat Biotech International Limited, Genome Valley, Shameerpet, Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venugopal","family":"Potula","sequence":"additional","affiliation":[{"name":"King George Hospital, Maharanipeta, Vishakhapatnam, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasant","family":"Khalatkar","sequence":"additional","affiliation":[{"name":"Colours Children Hospital, Jasleen, Pachsheel Square, Nagpur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niranjana S","family":"Mahantshetty","sequence":"additional","affiliation":[{"name":"KLE Hospital, Belgavi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atish","family":"Shah","sequence":"additional","affiliation":[{"name":"Sangini Hospital, Ahmedabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raches","family":"Ella","sequence":"additional","affiliation":[{"name":"Bharat Biotech International Limited, Genome Valley, Shameerpet, Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,20]]},"reference":[{"key":"2020110419122654600_CIT0001","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2471\/BLT.10.085233","article-title":"Estimated global incidence of Japanese encephalitis: a systematic review","volume":"89","author":"Campbell","year":"2011","journal-title":"Bull World Health Organ"},{"key":"2020110419122654600_CIT0002","doi-asserted-by":"crossref","first-page":"930","DOI":"10.4269\/ajtmh.2010.09-0676","article-title":"Japanese encephalitis in travelers from non-endemic countries, 1973\u20132008","volume":"82","author":"Hills","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"2020110419122654600_CIT0003","first-page":"69","article-title":"Japanese Encephalitis Vaccines: WHO position paper","volume":"90","year":"2015","journal-title":"Releve epidemiologique hebdomadaire\/Section d\u2019hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record\/Health Section of the Secretariat of the League of Nations"},{"key":"2020110419122654600_CIT0004","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1016\/j.vaccine.2010.02.105","article-title":"Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities","volume":"28","author":"Yu","year":"2010","journal-title":"Vaccine"},{"key":"2020110419122654600_CIT0005","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.vaccine.2008.12.062","article-title":"Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study","volume":"27","author":"Schuller","year":"2009","journal-title":"Vaccine"},{"key":"2020110419122654600_CIT0006","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1016\/j.vaccine.2008.05.081","article-title":"Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study","volume":"26","author":"Schuller","year":"2008","journal-title":"Vaccine"},{"key":"2020110419122654600_CIT0007"},{"key":"2020110419122654600_CIT0008","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/infdis\/jiv023","article-title":"A Japanese encephalitis vaccine from India induces durable and cross-protective immunity against temporally and spatially wide-ranging global field strains","volume":"212","author":"Singh","year":"2015","journal-title":"J Infect Dis"},{"key":"2020110419122654600_CIT0009","first-page":"1","article-title":"Isolation of Japanese encephalitis & West Nile viruses from peripheral blood of encephalitis patients","volume":"79","author":"Kedarnath","year":"1984","journal-title":"Indian J Med Res"},{"key":"2020110419122654600_CIT0010"},{"key":"2020110419122654600_CIT0011"},{"key":"2020110419122654600_CIT0012","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(05)67567-8","article-title":"Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study","volume":"366","author":"Ohrr","year":"2005","journal-title":"Lancet"},{"key":"2020110419122654600_CIT0013","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3346\/jkms.2015.30.5.612","article-title":"The immunogenicity and safety of the live-attenuated SA 14-14-2 Japanese encephalitis vaccine given with a two-dose primary schedule in children","volume":"30","author":"Kwon","year":"2015","journal-title":"J Korean Med Sci"},{"key":"2020110419122654600_CIT0014","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/S0264-410X(99)00006-7","article-title":"Primary and booster immune responses to SA14-14-2 Japanese encephalitis vaccine in Korean infants","volume":"17","author":"Sohn","year":"1999","journal-title":"Vaccine"},{"key":"2020110419122654600_CIT0015","doi-asserted-by":"crossref","first-page":"214","DOI":"10.4269\/ajtmh.1988.39.214","article-title":"Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14-14-2) for children","volume":"39","author":"Xin","year":"1988","journal-title":"Am J Trop Med Hyg"},{"key":"2020110419122654600_CIT0016","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s13312-013-0292-9","article-title":"Indian Academy of Pediatrics (IAP) recommended immunization schedule for children aged 0 through 18 years, India, 2013 and updates on immunization","volume":"50","author":"Vashishtha","year":"2013","journal-title":"Indian Pediatr"},{"key":"2020110419122654600_CIT0017","doi-asserted-by":"crossref","first-page":"e0005263","DOI":"10.1371\/journal.pntd.0005263","article-title":"Cellular immune responses to live attenuated Japanese encephalitis (JE) vaccine SA14-14-2 in adults in a JE\/dengue co-endemic area","volume":"11","author":"Turtle","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110419122654600_CIT0018","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/ijmr.IJMR_712_16","article-title":"Coverage & missed opportunity for Japanese encephalitis vaccine, Gorakhpur division, Uttar Pradesh, India, 2015: implications for Japanese encephalitis control","volume":"145","author":"Murhekar","year":"2017","journal-title":"Indian J Med Res"},{"key":"2020110419122654600_CIT0019","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0264-410X(02)00772-7","article-title":"Establishment of an analyzing method for a Japanese encephalitis virus neutralization test in Vero cells","volume":"21","author":"Abe","year":"2003","journal-title":"Vaccine"},{"key":"2020110419122654600_CIT0020","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","article-title":"Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2\u20133 September, 2004","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"},{"key":"2020110419122654600_CIT0021","article-title":"Ministry of Health, India, Directorate of National Vector Borne Disease Control Programme-Delhi. State wise number of AES\/JE Cases and Deaths from 2013-2019 (till June)"},{"key":"2020110419122654600_CIT0022","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1097\/INF.0000000000001615","article-title":"Immunogenicity of the inactivated Japanese encephalitis virus vaccine IXIARO in children from a Japanese encephalitis virus-endemic region","volume":"36","author":"Dubischar","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"2020110419122654600_CIT0023","doi-asserted-by":"crossref","first-page":"7852","DOI":"10.1073\/pnas.1607931113","article-title":"Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus","volume":"113","author":"Priyamvada","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020110419122654600_CIT0024","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1186\/s12879-016-1873-8","article-title":"Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults","volume":"16","author":"Saito","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2020110419122654600_CIT0025","author":"National Vector Borne Disease Control Program, Ministry of Health, India. National Guidelines for Clinical Management of Dengue"},{"key":"2020110419122654600_CIT0026"},{"key":"2020110419122654600_CIT0027","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1097\/INF.0000000000002124","article-title":"Antibody persistence up to 3 years after primary immunization with inactivated Japanese encephalitis vaccine IXIARO in Philippine children and effect of a booster dose","volume":"37","author":"Kadlecek","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"2020110419122654600_CIT0028"},{"key":"2020110419122654600_CIT0029","article-title":"Department of Health and Family Welfare, Ministry of Health and Family Welfare. New Delhi, India: Government of India. Disease control programmes (NHM). Chapter 5. In: Annual Report 2016\u201317."},{"key":"2020110419122654600_CIT0030","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jiph.2018.04.011","article-title":"Effectiveness of Japanese encephalitis SA 14-14-2 live attenuated vaccine among Indian children: retrospective 1:4 matched case-control study","volume":"11","author":"Tandale","year":"2018","journal-title":"J Infect Public Health"},{"key":"2020110419122654600_CIT0031","doi-asserted-by":"crossref","first-page":"896749","DOI":"10.1155\/2013\/896749","article-title":"Incidence of Japanese encephalitis among acute encephalitis syndrome cases in West Bengal, India","volume":"2013","author":"Bandyopadhyay","year":"2013","journal-title":"Biomed Res Int"},{"key":"2020110419122654600_CIT0032","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4103\/0377-4929.138732","article-title":"An appraisal of clinicopathological parameters in Japanese encephalitis and changing epidemiological trends in upper Assam, India","volume":"57","author":"Patgiri","year":"2014","journal-title":"Indian J Pathol Microbiol"},{"key":"2020110419122654600_CIT0033","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jinf.2017.09.018","article-title":"Epidemiology","volume":"76","author":"Kanagasabai","year":"2017","journal-title":"J Infect"},{"key":"2020110419122654600_CIT0034","doi-asserted-by":"crossref","first-page":"311","DOI":"10.4103\/0972-9062.225835","article-title":"Aetiology of acute encephalitis syndrome in Uttar Pradesh, India from 2014 to 2016","volume":"54","author":"Jain","year":"2017","journal-title":"J Vector Borne Dis"},{"key":"2020110419122654600_CIT0035","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4103\/ijmr.IJMR_1303_15","article-title":"Incidence of Japanese encephalitis amongst acute encephalitis syndrome cases in upper Assam districts from 2012 to 2014: a report from a tertiary care hospital","volume":"146","author":"Medhi","year":"2017","journal-title":"Indian J Med Res"},{"key":"2020110419122654600_CIT0036","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/INF.0000000000002099","article-title":"Acute encephalitis","volume":"37","author":"Mittal","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"2020110419122654600_CIT0037"},{"key":"2020110419122654600_CIT0038","first-page":"549","article-title":"Studies of missed opportunities for immunization in developing and industrialized countries","volume":"71","author":"Hutchins","year":"1993","journal-title":"Bull World Health Organ"},{"key":"2020110419122654600_CIT0039","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/j.vaccine.2011.01.058","article-title":"Long term immunity following a booster dose of the inactivated Japanese encephalitis vaccine IXIARO\u00ae, IC51","volume":"29","author":"Eder","year":"2011","journal-title":"Vaccine"},{"key":"2020110419122654600_CIT0040","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1016\/j.vaccine.2015.05.037","article-title":"Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis","volume":"33","author":"Paulke-Korinek","year":"2015","journal-title":"Vaccine"},{"key":"2020110419122654600_CIT0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2017.1285472","article-title":"Japanese encephalitis vaccines: immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease","volume":"13","author":"Hegde","year":"2017","journal-title":"Hum Vaccin Immunother"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiz672\/31790256\/jiz672.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/222\/9\/1478\/33828448\/jiz672.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/222\/9\/1478\/33828448\/jiz672.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:57:27Z","timestamp":1604537847000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/222\/9\/1478\/5681576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,20]]},"references-count":41,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,12,20]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiz672","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11,1]]},"published":{"date-parts":[[2019,12,20]]}}}